Osteoblast differentiation and control by vitamin D and vitamin D metabolites

Current Pharmaceutical Design

Volumn 10, Issue 21, 2004, Pages 2535-2555

  van Driel, M ^a   Pols, H A P ^a   van Leeuwen, J P T M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

24 hydroxylase; Analogs; Bone formation; Osteoblast; Vitamin D; Vitamin D receptor

Indexed keywords

1,24,25 TRIHYDROXYCOLECALCIFEROL; 24,25 DIHYDROXYCOLECALCIFEROL; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN; CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM; COLLAGEN TYPE 1; COLLAGENASE; DEXAMETHASONE; GROWTH FACTOR; MATRIX METALLOPROTEINASE; MATRIX PROTEIN; MESSENGER RNA; OSTEOCALCIN; OSTEOPONTIN; OXYGENASE; PLASMINOGEN; PROSTAGLANDIN E2; SEOCALCITOL; SIALOPROTEIN; SOMATOMEDIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; VITAMIN K GROUP;

APOPTOSIS; BONE DISEASE; BONE METABOLISM; BONE MINERALIZATION; CALCIUM HOMEOSTASIS; CELL ACTIVITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; COLLAGEN SYNTHESIS; DRUG MECHANISM; ENZYME ACTIVITY; FRAGILITY FRACTURE; GENE EXPRESSION; HUMAN; INVOLUTIONAL OSTEOPOROSIS; MOLECULAR INTERACTION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; VITAMIN D METABOLISM; VITAMIN D RESISTANT RICKETS;

ANIMALS; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CYTOCHROME P-450 ENZYME SYSTEM; GROWTH SUBSTANCES; HUMANS; HYDROXYLATION; OSTEOBLASTS; RECEPTORS, CALCITRIOL; STEROID HYDROXYLASES; VITAMIN D;

EID: 3242887187     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383818     Document Type: Review

References (351)

1. Fujita T. Vitamin D in the treatment of osteoporosis. Proc Soc Exp Biol Med 1992; 199: 394-399.
2. Fujita T. Vitamin D in the treatment of osteoporosis revisited. Proc Soc Exp Biol Med 1996; 212: 110-115.
3. Gallagher JC, Riggs BL, Recker RR, Goldgar D. The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc Soc Exp Biol Med 1989; 191: 287-292.
4. Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium [see comments]. N Engl J Med 1992; 326: 357-362.
5. 3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327: 1637-1642.
6. Francis RM. Is there a differential response to alfacalcidol and vitamin D in the treatment of osteoporosis? Calcif Tissue Int 1997; 60: 111-114.
7. Gillespie WJ, Avenell A, Henry DA, O'Connell DL, Robertson J. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2001; CD000227-
8. Balsan S, Garabedian M, Larchet M, Gorski AM, Cournot G, Tau C, et al. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. J Clin Invest 1986; 77: 1661-1667.
9. Weisman Y, Bab I, Gazit D, Spirer Z, Jaffe M, Hochberg Z. Long-term intracaval calcium infusion therapy in end-organ resistance to 1,25-dihydroxyvitamin D Am J Med 1987; 83: 984-990.
10. Bliziotes M, Yergey AL, Nanes MS, Muenzer J, Begley MG, Vieira NE, et al. Absent intestinal response to calciferols in hereditary resistance to 1,25-dihydroxyvitamin D: documentation and effective therapy with high dose intravenous calcium infusions. J Clin Endocrinol Metab 1988; 66: 294-300.
11. al Aqeel A, Ozand P, Sobki S, Sewairi W, Marx S. The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII). Clin Endocrinol (Oxf) 1993; 39: 229-237.
12. Amling M, Priemel M, Holzmann T, Chapin K, Rueger JM, Baron R, et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses Endocrinology 1999; 140: 4982-4987.
13. 3 receptor in fetal rat bone. J Bone Miner Res 1996; 11: 56-61.
14. Mee AP, Hoyland JA, Braidman IP, Freemont AJ, Davies M. Mawer EB. Demonstration of vitamin D receptor transcripts in actively resorbing osteoclasts in bone sections. Bone 1996; 18: 295-299.
15. Langub MC, Reinhardt TA, Horst RL, Malluche HH, Koszewski NJ. Characterization of vitamin D receptor immunoreactivity in human bone cells. Bone 2000; 27: 383-387.
16. Gardiner EM, Baldock PA, Thomas GP, Sims NA, Henderson NK, Hollis B, et al. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage [In Process Citation]. FASEB J 2000; 14: 1908-1916.
17. 3 analogs to mice. J Endocrinol 2000; 165: 163-172.
18. 2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 2003; 112: 1906-1914.
19. St Arnaud R, Arabian A, Travers R, Barletta F, Raval-Pandya M, Chapin K, et al. Deficient mineralization of intramembranous bone in vitamin D-24- hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24, 25-dihydroxyvitamin D. Endocrinology 2000; 141: 2658-2666.
20. 3: increased bone but impaired mineralization. Endocrinology 1986; 119: 2580-2585.
21. 3 stimulates bone formation and increases the number of osteoblast precursor cells in bone marrow. Endocrinology 1997; 138: 4629-4635.
22. 3 on bone. Endocrinology 1998; 139: 4319-4328.
23. Stein GS, Lian JB, Stein JL, Van Wijnen AJ, Montecino M. Transcriptional control of osteoblast growth and differentiation. Physiol Rev 1996; 76: 593-629.
24. Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J Bone Miner Res 1992; 7: 683-692.
25. Choi JY, Lee BH, Song KB, Park RW, Kim IS, Sohn KY, et al. Expression patterns of bone-related proteins during osteoblastic differentiation in MC3T3-E1 cells. J Cell Biochem 1996; 61: 609-618.
26. Gerstenfeld LC, Chipman SD, Glowacki J, Lian JB. Expression of differentiated function by mineralizing cultures of chicken osteoblasts. Dev Biol 1987; 122: 49-60.
27. Cheng SL, Yang JW, Rifas L, Zhang SF, Avioli LV. Differentiation of human bone marrow osteogenic stromal cells in vitro: induction of the osteoblast phenotype by dexamethasone. Endocrinology 1994; 134: 277-286.
28. Siggelkow H, Rebenstorff K, Kurre W, Niedhart C, Engel I, Schulz H, et al. Development of the osteoblast phenotype in primary human osteoblasts in culture: comparison with rat calvarial cells in osteoblast differentiation. J Cell Biochem 1999; 75: 22-35.
29. Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000; 289: 1501-1504.
30. 3 on osteogenic differentiation of human marrow stromal cells in vitro. Arch Oral Biol 1994; 39: 941-947.
31. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. J Bone Miner Res 1998; 13: 371-382.
32. Hicok KC, Thomas T, Gori F, Rickard DJ, Spelsberg TC, Riggs BL. Development and characterization of conditionally immortalized osteoblast precursor cell lines from human bone marrow stroma. J Bone Miner Res 1998; 13: 205-217.
33. Beresford JN. Bennett JH, Devlin C, Leboy PS, Owen ME. Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci 1992; 102 ( Pt 2): 341-351.
34. 3 modulation in lipid metabolism in established bone marrow-derived stromal cells, MC3T3-G2/PA6. J Cell Biochem 1992; 48: 424-430.
35. 3 and the nonadherent cells of marrow for osteoblast differentiation from rat marrow stromal cells. Bone 1995; 16: 671-678.
36. 3 inhibits adipocyte differentiation and gene expression in murine bone marrow stromal cell clones and primary cultures. Endocrinology 1998; 139: 2622-2628.
37. Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, et al. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 1999; 140: 5060-5065.
38. 3 stimulates adipocyte differentiation in cultures of fetal rat calvaria cells: comparison with the effects of dexamethasone. Endocrinology 1994; 134: 2221-2229.
39. 3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 2002; 274: 323-333.
40. 3, dexamethasone, and local growth factors in primary human osteoblasts. J Cell Biochem 2002; 86: 348-356.
41. 3, dexamethasone, and local growth factors in primary human osteoblasts. J Cell Biochem 2002; 86: 348-356.
42. 3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 2002; 274: 323-333.
43. Tsuji K, Kraut N, Groudine M, Noda M. Vitamin D(3) enhances the expression of I-mfa, an inhibitor of the MyoD family, in osteoblasts. Biochim Biophys Acta 2001; 1539: 122-130
44. Schnabel M, Fichtel I, Gotzen L, Schlegel J. Differential expression of Notch genes in human osteoblastic cells. Int J Mol Med 2002; 9: 229-232.
45. 3-analogs on osteoblast- like cells and on in vitro bone resorption. J Steroid Biochem Mol Biol 1995; 55: 337-346.
46. 3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements. Endocrinology 1996; 137: 2001-2011.
47. Lian JB, Shalhoub V, Aslam F, Frenkel B, Green J, Hamrah M, et al. Species-specific glucocorticoid and 1,25-dihydroxyvitamin D responsiveness in mouse MC3T3-E1 osteoblasts: dexamethasone inhibits osteoblast differentiation and vitamin D down-regulates osteocalcin gene expression. Endocrinology 1997; 138: 2117-2127.
48. Aubin J, Candeliere G, Bonnelye E. The heterogeneity of the osteoblast phenotype. The Endocrinologist 1999; 25-31.
49. Narisawa S, Frohlander N, Millan JL. Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Dev Dyn 1997; 208: 432-446.
50. Hui M, Tenenbaum HC. New face of an old enzyme: alkaline phosphatase may contribute to human tissue aging by inducing tissue hardening and calcification. Anat Rec 1998; 253: 91-94.
51. 3 stimulates the alkaline phosphatase activity of osteoblast-like cells. J Biol Chem 1981; 256: 7115-7117.
52. Imai K, Neuman MW, Kawase T, Saito S. Calcium in osteoblast-enriched bone cells. Bone 1992; 13: 217-223.
53. Anderson HC. Mechanism of mineral formation in Bone Lab Invest 1989; 60: 320-330.
54. Beck GR Jr, Sullivan EC, Moran E, Zerler B. Relationship between alkaline phosphatase levels, osteopontin expression, and mineralization in differentiating MC3T3-E1 osteoblasts. J Cell Biochem 1998; 68: 269-280.
55. 2 vitamin D3-induced mineralization in human periosteal osteoblasts. Calcif Tissue Int 1996; 59: 466-473.
56. Koshihara Y, Hirano M, Kawamura M, Oda H, Higaki S. Mineralization ability of cultured human osteoblast-like periosteal cells does not decline with aging. J Gerontol 1991; 46: B201-B206.
57. Halvorsen YD, Franklin D, Bond AL, Hitt DC, Auchter C, Boskey AL, et al. Extracellular matrix mineralization and osteoblast gene expression by human adipose tissue-derived stromal cells. Tissue Eng 2001; 7: 729-741.
58. 3, parathyroid hormone, and dexamethasone. J Bone Miner Res 1994; 9: 1259-1266.
59. Slater M, Patava J, Mason RS. Role of chondroitin sulfate glycosaminoglycans in mineralizing osteoblast-like cells: effects of hormonal manipulation. J Bone Miner Res 1994; 9: 161-169.
60. 3 on phospholipid metabolism in a clonal osteoblast-like rat osteogenic sarcoma cell line. J Biol Chem 1985; 260: 13704-13709.
61. Balmain N, Berdal A, Hotton D, Cuisinier-Gleizes P, Mathieu H. Calbindin-D9K immunolocalization and vitamin D-dependence in the Bone of growing and adult rats. Histochemistry 1989; 92: 359-365.
62. Lynch MP, Stein JL, Stein GS, Lian JB. The influence of type 1 collagen on the development and maintenance of the osteoblast phenotype in primary and passaged rat calvarial osteoblasts: modification of expression of genes supporting cell growth, adhesion, and extracellular matrix mineralization. Exp Cell Res 1995; 216: 35-45.
63. 3 of in vitro mineralization induced by osteoblast-like MC3T3-E1 cells Bone 1991; 12: 27-32.
64. St Arnaud R, Prud'homme J, Leung-Hagesteijn C, Dedhar S. Constitutive expression of calreticulin in osteoblasts inhibits mineralization. J Cell Biol 1995; 131: 1351-1359.
65. 3 down-regulates expression of Phex, a marker of the mature osteoblast. Endocrinology 1999; 140: 1192-1199.
66. Misof BM, Roschger P, Tesch W, Baldock PA, Valenta A, Messmer P, et al. Targeted overexpression of vitamin D receptor in osteoblasts increases calcium concentration without affecting structural properties of Bone mineral crystals. Calcif Tissue Int 2003; 73: 251-257.
67. Thomas G, Moffatt P, Salois P, Gaumond MH, Gingras R, Godin E, et al. Osteocrin, a Novel Bone -specific Secreted Protein That Modulates the Osteoblast Phenotype. J Biol Chem 2003; 278: 50563-50571.
68. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001; 21: 1610-1616.
69. Lynch MP, Capparelli C, Stein JL, Stein GS, Lian JB. Apoptosis during Bone -like tissue development in vitro. J Cell Biochem 1998; 68: 31-49.
70. Landry P, Sadasivan K, Marino A, Albright J. Apoptosis is coordinately regulated with osteoblast formation during Bone healing. Tissue Cell 1997; 29: 413-419.
71. Mathijssen I, van Leeuwen J, Vermeij-Keers C. Simultaneous induction of apoptosis, Collagen type I expression and mineralization in the developing coronal suture following FGF4 and FGF2 application. J Craniofacial Genetics and Developmental Biology 2001; in press.
72. Mansukhani A, Bellosta P, Sahni M, Basilico C. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol 2000; 149: 1297-1308.
73. Hansen CM, Hansen D, Holm PK, Binderup L. Vitamin D compounds exert anti-apoptotic effects in human osteosarcoma cells in vitro. J Steroid Biochem Mol Biol 2001; 77: 1-11.
74. 3 on TNF alpha-mediated apoptosis of human primary osteoblast-like cells in vitro. Horm Metab Res 1999; 31: 653-656.
75. 3 recombinant human transforming growth factor- beta 1, and recombinant human Bone morphogenetic protein-2 induce in vitro differentiation of canine osteosarcoma cells. J Vet Med Sci 1999; 61: 649-656.
76. 3 Inhibits GH-induced Expression of SOCS-3 and CIS and Prolongs Growth Hormone Signaling via the Janus Kinase (JAK2)/Signal Transducers and Activators of Transcription (STAT5) System in Osteoblast-like Cells. J Biol Chem 2002; 277: 34879-34884.
77. Nur T, Peijnenburg AA, Notcborn HP, Baykus H, Reifen R. DNA microarray technology reveals similar gene expression patterns in rats with vitamin a deficiency and chemically induced colitis. J Nutr 2002; 132: 2131-2136.
78. 3 and glucocorticoids on the growth of rat and mouse osteoblast-like Bone cells. Calcif Tissue Int 1983; 35: 806-811.
79. 3 regulation of proliferation and alkaline phosphatase activity in late-passage rat osteoblastic cell lines. J Steroid Biochem Mol Biol 1993; 46: 227-233.
80. Urano T, Hosoi T, Shiraki M, Toyoshima H, Ouchi Y, Inoue S. Possible involvement of the p57(Kip2) gene in Bone metabolism. Biochem Biophys Res Common 2000; 269: 422-426.
81. Atmani H, Chappard D, Basle MF. Proliferation and differentiation of osteoblasts and adipocytes in rat Bone marrow stromal cell cultures: effects of dexamethasone and calcitriol. J Cell Biochem 2003; 89: 364-372.
82. 3 on the proliferation of osteoblastic MC3T3-E1 cells by modulating the release of local regulators from monocytes. Biochem Biophys Res Commun 1993; 190: 529-535.
83. 3. Calcif Tissue Int 1996; 59: 291-296.
84. Taira M, Nakao H, Takahashi J, Araki Y. Effects of two vitamins, two growth factors and dexamethasone on the proliferation of rat Bone marrow stromal cells and osteoblastic MC3T3-E1 cells. J Oral Rehabil 2003; 30: 697-701.
85. 3 in cultured mouse osteoblast-like cells-modulation by changes in receptor level. J Cell Physiol 1986; 126: 21-28.
86. Watts NB. Clinical utility of biochemical markers of Bone remodeling. Clin Chem 1999; 45: 1359-1368.
87. Bodine PV, Vernon SK, Komm BS. Establishment and hormonal regulation of a conditionally transformed preosteocytic cell line from adult human Bone Endocrinology 1996; 137: 4592-4604.
88. 3 attenuates the confluence-dependent differences in the osteoblast characteristic proteins alkaline phosphatase, procollagen I peptide, and osteocalcin. Calcif Tissue Int 1999; 64: 414-421.
89. Andrianarivo AG, Robinson JA, Mann KG, Tracy RP. Growth on type I collagen promotes expression of the osteoblastic phenotype in human osteosarcoma MG-63 cells. J Cell Physiol 1992; 153: 256-265.
90. 3. Metabolism 1992; 41: 42-48.
91. 3 on the function, cytochemistry and morphology of normal human osteoblast-like cells. Differentiation 1994; 55: 153-163.
92. Kassem M, Kveiborg M, Eriksen EF. Production and action of transforming growth factor-beta in human osteoblast cultures: dependence on cell differentiation and modulation by calcitriol. Eur J Clin Invest 2000; 30: 429-437.
93. Lomri A, Marie PJ, Tran PV, Hott M. Characterization of endosteal osteoblastic cells isolated from mouse caudal vertebrae. Bone 1988; 9: 165-175.
94. Halstead LR, Scott MJ, Rifas L, Avioli LV. Characterization of osteoblast-like cells from normal adult rat femoral trabecular Bone Calcif Tissue Int 1992; 50: 93-95.
95. Owen TA, Aronow MS, Barone LM, Bettencourt B, Stein GS, Lian JB. Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the Bone cell phenotype: dependency upon basal levels of gene expression, duration of exposure, and Bone matrix competency in normal rat osteoblast cultures. Endocrinology 1991; 128: 1496-1504.
96. 3 in human osteosarcoma cells. J Biol Chem 1988; 263: 18938-18945.
97. Tasaki Y, Takamori R, Koshihara Y. Prostaglandin D2 metabolite stimulates collagen synthesis by human osteoblasts during calcification. Prostaglandins 1991; 41: 303-313.
98. 3 potentiates fluoride-stimulated collagen type I production in cultures of human Bone marrow stromal osteoblast-like cells. J Bone Miner Res 1993; 8: 1453-1458.
99. Holliday LS, Welgus HG, Fliszar CJ, Veith GM, Jeffrey JJ, Gluck SL. Initiation of osteoclast Bone resorption by interstitial collagenase. J Biol Chem 1997; 272: 22053-22058.
100. Meikle MC, Bord S, Hembry RM, Compston J, Croucher PI, Reynolds JJ. Human osteoblasts in culture synthesize collagenase and other matrix metalloproteinases in response to osteotropic hormones and cytokines. J Cell Sci 1992; 103 ( Pt 4): 1093-1099.
101. 3 inhibits transcription of type I collagen genes in the rat osteosarcoma cell line ROS 17/2.8. Endocrinology 1989; 125: 327-333.
102. 3 interaction with dexamethasone and retinoic acid: effects on procollagen messenger ribonucleic acid levels in rat osteoblast-like cells. Mol Endocrinol 1989; 3: 97-104.
103. 3 inhibition of colla1 promoter expression in calvariae from neonatal transgenic mice. Biochim Biophys Acta 1998; 1398: 285-293.
104. 3 and inhibited by human recombinant TIMP (tissue inhibitor of metalloproteinases). Biochem Biophys Res Commun 1987; 148: 596-602.
105. Thomson BM, Atkinson SJ, McGarrity AM, Hembry RM, Reynolds JJ, Meikle MC. Type I collagen degradation by mouse calvarial osteoblasts stimulated with 1,25-dihydroxyvitamin D-3: evidence for a plasminogen-plasmin- metalloproteinase activation cascade. Biochim Biophys Acta 1989; 1014: 125-132.
106. Meikle MC, McGarrity AM, Thomson BM, Reynolds JJ. Bone - derived growth factors modulate collagenase and TIMP (tissue inhibitor of metalloproteinases) activity and type I collagen degradation by mouse calvarial osteoblasts. Bone Miner 1991; 12: 41-55.
107. Christenson RH. Biochemical markers of Bone metabolism: an overview. Clin Biochem 1997; 30: 573-593.
108. 3 promotes vitamin K2 metabolism in human osteoblasts. Osteoporos Int 2001; 12: 680-687.
109. Weber P. Management of osteoporosis: is there a role for vitamin K? Int J Vitam Nutr Res 1997; 67: 350-356.
110. Hoang QQ, Sicheri F, Howard AJ, Yang DS. Bone recognition mechanism of porcine osteocalcin from crystal structure. Nature 2003; 425: 977-980.
111. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, et al. Increased Bone formation in osteocalcin-deficient mice. Nature 1996; 382: 448-452.
112. Lajeunesse D, Kiebzak GM, Frondoza C, Sacktor B. Regulation of osteocalcin secretion by human primary Bone cells and by the human osteosarcoma cell line MG-63. Bone Miner 1991; 14: 237-250.
113. 3, parathyroid hormone, and glucocorticoids. Metab Bone Dis Relat Res 1984; 5: 229-234.
114. Skjodt H, Gallagher JA, Beresford JN, Couch M, Poser JW, Russell RG. Vitamin D metabolites regulate osteocalcin synthesis and proliferation of human Bone cells in vitro. J Endocrinol 1985; 105: 391-396.
115. Hosoda K, Kanzaki S, Eguchi H, Kiyoki M, Yamaji T, Koshihara Y, et al. Secretion of osteocalcin and its propeptide from human osteoblastic cells: dissociation of the secretory patterns of osteocalcin and its propeptide. J Bone Miner Res 1993; 8: 553-565.
116. Lajeunesse D, Frondoza C, Schoffield B, Sacktor B. Osteocalcin secretion by the human osteosarcoma cell line MG-63. J Bone Miner Res 1990; 5: 915-922.
117. Lian J, Stewart C, Puchacz E, Mackowiak S, Shalhoub V, Collart D, et al. Structure of the rat osteocalcin gene and regulation of vitamin D- dependent expression. Proc Natl Acad Sci USA 1989; 86: 1143-1147.
118. 3. Arch Biochem Biophys 1996; 332: 142-152.
119. 3. Cell Tissue Res 1999; 297: 249-259.
120. Stein GS, Lian JB, Owen TA. Bone cell differentiation: a functionally coupled relationship between expression of cell-gr. Curr Opin Cell Biol 1990; 2: 1018-1027.
121. Owen TA, Bortell R, Yocum SA, Smock SL, Zhang M, Abate C, et al. Coordinate occupancy of AP-1 sites in the vitamin D-responsive and CCAAT box elements by Fos-Jun in the osteocalcin gene: model for phenotype suppression of transcription. Proc Natl Acad Sci USA 1990; 87: 9990-9994.
122. Stein GS, Lian JB. Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 1993; 14: 424-442.
123. Shalhoub V, Aslam F, Breen E, van Wijnen A, Bortell R, Stein GS, et al. Multiple levels of steroid hormone-dependent control of osteocalcin during osteoblast differentiation: glucocorticoid regulation of basal and vitamin D stimulated gene expression. J Cell Biochem 1998; 69: 154-168.
124. 3 in mouse long Bone s: interaction with the Bone - derived growth factors TGF-beta and IGF-I. J Bone Miner Res 1998; 13: 36-43.
125. 3 inhibits Osteocalcin expression in mouse through an indirect mechanism. J Biol Chem 1997; 272: 110-116.
126. Chen TL, Fry D. Hormonal regulation of the osteoblastic phenotype expression in neonatal murine calvarial cells. Calcif Tissue Int 1999; 64: 304-309.
127. 3 on collagen type I, osteopontin, and osteocalcin gene expression in chicken osteoblasts. J Cell Biochem 1995; 57: 440-451.
128. Price PA. Gla-containing proteins of Bone Connect Tissue Res 1989; 21: 51-57.
129. Shearer MJ. Role of vitamin K and gla proteins in the pathophysiology of osteoporosis and vascular calcification [In Process Citation]. Curr Opin Clin Nutr Metab Care 2000; 3: 433-438.
130. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81.
131. Pinto JP, Conceicao N, Gavaia PJ, Cancela ML. Matrix Gla protein gene expression and protein accumulation colocalize with cartilage distribution during development of the teleost fish Sparus aurata. Bone 2003; 32: 201-210.
132. Cancela L, Hsieh CL, Francke U, Price PA. Molecular structure, chromosome assignment, and promoter organization of the human matrix Gla protein gene. J Biol Chem 1990; 265: 15040-15048.
133. 3 stimulates the synthesis of matrix gamma- carboxyglutamic acid protein by osteosarcoma cells. Mutually exclusive expression of vitamin K-dependent Bone proteins by clonal osteoblastic cell lines. J Biol Chem 1988; 263: 911-916.
134. 3 treatment of osteosarcoma cells. Calcif Tissue Int 1990; 46: 270-279.
135. Barone LM, Owen TA, Tassinari MS, Bortell R, Stein GS, Lian JB. Developmental expression and hormonal regulation of the rat matrix Gla protein (MGP) gene in chondrogenesis and osteogenesis. J Cell Biochem 1991; 46: 351-365.
136. Reinholt FP, Hultenby K, Oldberg A, Heinegard D. Osteopontin - a possible anchor of osteoclasts to Bone Proc Natl Acad Sci USA 1990; 87: 4473-4475.
137. Yoshitake H, Rittling SR, Denhardt DT, Noda M. Osteopontin-deficient mice are resistant to ovariectomy-induced Bone resorption [published erratum appears in Proc Natl Acad Sci U S A 1999 Sep 14;96(19):10944]. Proc Natl Acad Sci USA 1999; 96: 8156-8160.
138. Johnson K, Goding J, Van Etten D, Sali A, Hu SI, Farley D, et al. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 2003; 18: 994-1004.
139. Landis WJ, Jacquet R, Hillyer J, Zhang J. Analysis of osteopontin in mouse growth plate cartilage by application of laser capture microdissection and RT-PCR. Connect Tissue Res 2003; 44 Suppl 1: 28-32.
140. Fernandez MS, Escobar C, Lavelin I, Pines M, Arias JL. Localization of osteopontin in oviduct tissue and eggshell during different stages of the avian egg laying cycle. J Struct Biol 2003; 143: 171-180.
141. Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Stietz S, Giachelli C, et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 2003; 14: 139-147.
142. Rittling SR, Matsumoto HN, McKee MD, Nanci A, An XR, Novick KE, et al. Mice lacking osteopontin show normal development and Bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 1998; 13: 1101-1111.
143. 3-induced 24-hydroxylase activity in osteoblast-like cells: initiation of the C24-oxidation pathway. Bone 1997; 20: 237-243.
144. 3 regulates the biosynthesis of osteopontin, a Bone -derived cell attachment protein, in clonal osteoblast-like osteosarcoma cells. Coll Relat Res 1987; 7: 305-313.
145. 3 in rat Bone organ cultures. Connect Tissue Res 1996; 34: 41-51.
146. 3 enhancement of osteopontin gene expression. Bone 1997; 20: 329-334.
147. Jin CH, Miyaura C, Ishimi Y, Hong MH, Sato T, Abe E, et al. Interleukin 1 regulates the expression of osteopontin mRNA by osteoblasts. Mol Cell Endocrinol 1990; 74: 221-228.
148. Wainwright SA, Biggs WD, Currey JD, Gosline JM. Mechanical desigh in organisms. 1976;
149. Burr DB, Turner CH. Biomechanics of Bone 2003; Fifth: 58-64.
150. Derkx P, Nigg AL, Bosman FT, Birkenhager-Frenkel DH, Houtsmuller AB, Pols HA, et al. Immunolocalization and quantification of noncollagenous Bone matrix proteins in methylmethacrylate-embedded adult human Bone in combination with histomorphometry. Bone 1998; 22: 367-373.
151. Glowacki J, Rey C, Cox K, Lian J. Effects of Bone matrix components on osteoclast differentiation. Connect Tissue Res 1989: 20: 121-129.
152. Glowacki J, Lian JB. Impaired recruitment and differentiation of osteoclast progenitors by osteocalcin-deplete Bone implants. Cell Differ 1987; 21: 247-254.
153. Liggett WH Jr, Lian JB, Greenberger JS, Glowacki J. Osteocalcin promotes differentiation of osteoclast progenitors from murine long-term Bone marrow cultures. J Cell Biochem 1994; 55: 190-199.
154. Miyauchi A, Alvarez J, Greenfield EM, Teti A, Grano M, Colucci S, et al. Binding of osteopontin to the osteoclast integrin alpha v beta 3. Osteoporos Int 1993; 3 Suppl 1: 132-135.
155. Miyauchi A, Alvarez J, Greenfield EM, Teti A, Grano M, Colucci S, et al. Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 1991; 266: 20369-20374.
156. Kitazawa R, Kitazawa S. Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun 2002; 290: 650-655.
157. 3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem 2003; 89: 771-777.
158. Shibata T, Shira-Ishi A, Sato T, Masaki T, Masuda A, Hishiya A, et al. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in Bone marrow. J Bone Miner Res 2002; 17: 622-629.
159. Ganss B, Kim RH, Sodek J. Bone sialoprotein. Crit Rev Oral Biol Med 1999; 10: 79-98.
160. 3-response element that overlaps a unique inverted TATA box in the rat Bone sialoprotein gene. Biochem J 1996; 318 ( Pt 1): 219-226.
161. Oldberg A, Jirskog-Hed B, Axelsson S, Heinegard D. Regulation of Bone sialoprotein mRNA by steroid hormones. J Cell Biol 1989; 109: 3183-3186.
162. Heberden C, Denis I, Pointillart A, Mercier T. TGF-beta and calcitriol. Gen Pharmacol 1998; 30: 145-151.
163. 3 response elements in the human transforming growth factor beta 2 gene. Biochemistry 1999; 38: 2654-2660.
164. 3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human Bone cells. Biochem Biophys Res Commun 1997; 239: 734-739.
165. 3-mediated transforming growth factor-beta release is impaired in cultured osteoblasts from patients with multiple pituitary hormone deficiencies. J Bone Miner Res 1996; 11: 367-376.
166. Mustafa K, Rubinstein J, Lopez BS, Arvidson K. Production of transforming growth factor beta1 and prostaglandin E2 by osteoblast-like cells cultured on titanium surfaces blasted with TiO2 particles. Clin Oral Implants Res 2003; 14: 50-56.
167. 3 increases TGF beta 1 binding to human osteoblasts. Biochem Biophys Res Commun 2002; 290: 1558-1563.
168. Finkelman RD, Linkhart TA, Mohan S, Lau KH, Baylink DJ, Bell NH. Vitamin D deficiency causes a selective reduction in deposition of transforming growth factor beta in rat Bone: possible mechanism for impaired osteoinduction. Proc Natl Acad Sci USA 1991; 88: 3657-3660.
169. 3 17 beta-estradiol, and testosterone is age dependent in primary cultures of mouse-derived osteoblasts in vitro. Endocrine 1999; 11: 13-22.
170. Wang EA, Rosen V, D'Alessandro JS, Bauduy M, Cordes P, Harada T, et al. Recombinant human Bone morphogenetic protein induces Bone formation. Proc Natl Acad Sci USA 1990; 87: 2220-2224.
171. Virdi AS, Cook LJ, Oreffo RO, Triffitt JT. Modulation of Bone morphogenetic protein-2 and Bone morphogenetic protein-4 gene expression in osteoblastic cell lines. Cell Mol Biol (Noisy.-legrand) 1998; 44: 1237-1246.
172. 3 on Bone morphogenetic protein-3 mRNA expression. J Cell Biochem 1999; 73: 11-19.
173. Trippel SB. Potential role of insulinlike growth factors in fracture healing. Clin Orthop 1998; S301-S313.
174. Rosen CJ. Serum insulin-like growth factors and insulin-like growth factor- binding proteins: clinical implications. Clin Chem 1999; 45: 1384-1390.
175. Conover CA. Insulin-like growth factor binding protein proteolysis in Bone cell models. Prog Growth Factor Res 1995: 6: 301-309.
176. 3 and activity on human osteoblast-like cells in short- term cultures. Bone 1990; 11: 81-86.
177. 3 modulate the synthesis of insulin-like growth factor-I in osteoblast-like cells. Calcif Tissue Int 1991; 48: 278-282.
178. 3 differentially regulates the production of insulin-like growth factor I (IGF-I) and IGF-binding protein-4 in mouse osteoblasts. Endocrinology 1991; 129: 3139-3146.
179. McCarthy TL, Centrella M, Canalis E. Constitutive synthesis of insulin-like growth factor-II by primary osteoblast-enriched cultures from fetal rat calvariae. Endocrinology 1992; 130: 1303-1308.
180. 3. Endocrinology 1991; 128: 1511-1518.
181. 3 modulation of insulin-like growth factor-binding proteins in rat osteoblast-like cell cultures. Endocrinology 1991; 128: 73-80.
182. 3 increases secretion of insulin-like growth factor binding protein-4 (IGFBP-4) by human osteoblast-like cells in vitro and elevates IGFBP-4 serum levels in vivo. J Clin Endocrinol Metab 1993; 77: 1190-1197.
183. Nakao Y, Hilliker S, Baylink DJ, Mohan S. Studies on the regulation of insulin-like growth factor binding protein 3 secretion in human osteosarcoma cells in vitro. J Bone Miner Res 1994; 9: 865-872.
184. 3 stimulates the production of insulin-like growth factor-binding proteins-2, -3 and -4 in human Bone marrow stromal cells. Eur J Endocrinol 2001; 144: 549-557.
185. 3 increases IGF binding protein-5 expression in cultured osteoblasts. FEBS Lett 1996; 392: 21-24.
186. 3 on insulin-like growth factor-binding protein-5 mRNA expression in osteoblastic UMR-106 cells: the difference between transient and continuous treatments. FEBS Lett 1997; 409: 63-66.
187. Raisz LG. Prostaglandins and Bone: physiology and pathophysiology. Osteoarthritis.Cartilage 1999; 7: 419-421.
188. 3 pretreatment limits prostaglandin biosynthesis by cytokine-stimulated adult human osteoblast-like cells. J Cell Biochem 1998; 68: 237-246.
189. Marie PJ, Hott M, Launay JM, Graulet AM, Gueris J. In vitro production of cytokines by Bone surface-derived osteoblastic cells in normal and osteoporotic postmenopausal women: relationship with cell proliferation. J Clin Endocrinol Metab 1993; 77: 824-830.
190. 3 in three osteoblast-like cell lines (MC-3T3- E1, ROS 17/2.8, and MG-63). Bone 1992; 13: 51-58.
191. Martin TJ, Allan EH, Fukumoto S. The plasminogen activator and inhibitor system in Bone remodelling. Growth Regul 1993; 3: 209-214.
192. Allan EH, Martin TJ. The plasminogen activator inhibitor system in Bone cell function. Clin Orthop 1995; 54-63.
193. Hoekman K, Lowik CW, Ruit M, Bijvoet OL, Verheijen JH, Papapoulos SE. Regulation of the production of plasminogen activators by Bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells. Bone Miner 1991; 14: 189-204.
194. Merchiers P, Bulens F, Stockmans I, De Vriese A, Convents R, Bouillon R, et al. 1,25-Dihydroxyvitamin D(3) induction of the tissue-type plasminogen activator gene is mediated through its multihormone-responsive enhancer. FEBS Lett 1999; 460: 289-296.
195. 3 and activates protein C at their cell membrane. Endocrinology 1993; 133: 668-674.
196. Hamilton JA, Lingelbach SR, Partridge NC, Martin TJ. Stimulation of plasminogen activator in osteoblast-like cells by Bone - resorbing hormones. Biochem Biophys Res Commun 1984; 122: 230-236.
197. Hamilton JA, Lingelbach S, Partridge NC, Martin TJ. Regulation of plasminogen activator production by Bone -resorbing hormones in normal and malignant osteoblasts. Endocrinology 1985; 116: 2186-2191.
198. Uchida M, Shima M, Shimoaka T, Fujieda A, Obara K, Suzuki H, et al. Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by Bone resorptive factors in osteoblastic cells. J Cell Physiol 2000; 185: 207-214.
199. 3 in mouse osteoblastic MC3T3-E1 cells. J Bone Miner Res 2001; 16: 221-230.
200. 3 promotes vascularization of the chondro- osseous junction by stimulating expression of vascular endothelial growth factor and matrix metalloproteinase 9. J Bone Miner Res 2002; 17: 1604-1612.
201. 3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells. Mol Endocrinol 2001; 15: 1127-1139.
202. Farach-Carson MC, Xu Y. Microarray detection of gene expression changes induced by 1,25(OH)(2)D(3) and a Ca(2+) influx-activating analog in osteoblastic ROS 17/2.8 cells. Steroids 2002; 67: 467-470.
203. Swami S, Raghavachari N, Muller UR, Ban YP, Feldman D. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat 2003; 80: 49-62.
204. Li YC, Pirro AE, Amling M, Delling G, Baron R, Bronson R, et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 1997; 94: 9831-9835.
205. Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, et al. Mice lacking the vitamin D receptor exhibit impaired Bone formation, uterine hypoplasia and growth retardation after weaning. Natl Genet 1997; 16: 391-396.
206. 3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 1996; 58: 277-288.
207. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 1997; 126: 83-90.
208. Takeda S, Yoshizawa T, Nagai Y, Yamato H, Fukumoto S, Sekine K, et al. Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. Endocrinology 1999; 140: 1005-1008.
209. 3 reduces impairment of human osteoblast functions during cellular aging in culture. J Cell Physiol 2001; 186: 298-306.
210. Martinez P, Moreno I, De Miguel F, Vila V, Esbrit P, Martinez ME. Changes in osteocalcin response to 1,25-dihydroxyvitamin D(3) stimulation and basal vitamin D receptor expression in human osteoblastic cells according to donor age and skeletal origin. Bone 2001; 29: 35-41.
211. 3 receptor in rats. Biochem Biophys Res Commun 1986; 137: 742-747.
212. 3 receptors by blocking ubiquitin/proteasome-mediated degradation in human skin. Mol Endocrinol 1999; 13: 1686-1694.
213. Pols HA, Birkenhager JC, Schilte JP, Visser TJ. Evidence that the self-induced metabolism of 1,25-dihydroxyvitamin D-3 limits the homologous up-regulation of its receptor in rat osteosarcoma cells. Biochim Biophys Acta 1988; 970: 122-129.
214. 3 and parathyroid hormone. Biochim Biophys Acta 1996; 1312: 54-62.
215. 3 receptor levels and augments bioresponses in rat osteoblast-like cells. Endocrinology 1986, 118: 1119-1126.
216. Li XQ, Tembe V, Horwitz GM, Bushinsky DA, Favus MJ. Increased intestinal vitamin D receptor in genetic hypercalciuric rats. A cause of intestinal calcium hyperabsorption. J Clin Invest 1993; 91: 661-667.
217. 3 in Bone from genetic hypercalciuric rats. Am J Physiol 1996; 271: C130-C135.
218. Gensure RC, Antrobus SD, Fox J, Okwueze M, Talton SY, Walters MR. Homologous up-regulation of vitamin D receptors is tissue specific in the rat. J Bone Miner Res 1998; 13: 454-463.
219. 3: a steroid hormone capable of producing pleiotropic receptor-mediated biological responses by both genomic and nongenomic mechanisms. J Steroid Biochem 1988; 30: 33-39.
220. 3. J Cell Biochem 1994; 56: 303-306.
221. 3. J Cell Biochem 1994; 56: 510-517.
222. 3 metabolites on cytosolic free calcium in confluent mouse osteoblasts. J Biol Chem 1987; 262: 13168-13173.
223. 3 and its analogues in rat osteoblast-like cells. Biol Pharm Bull 1999; 22: 1058-1063.
224. 3- dependent transcaltachia (the rapid stimulation of duodenal Ca2+ transport). Endocrinology 1990; 127: 2475-2480.
225. 3 on the phosphoinositide metabolism in rat enterocytes. J Biol Chem 1989; 264: 20403-20406.
226. Civitelli R, Kim YS, Gunsten SL, Fujimori A, Huskey M, Avioli LV, et al. Nongenomic activation of the calcium message system by vitamin D metabolites in osteoblast-like cells. Endocrinology 1990; 127: 2253-2262.
227. 3 stimulates membrane phosphoinositide turnover, activates protein kinase C, and increases cytosolic calcium in rat colonic epithelium. J Clin Invest 1990; 85: 1296-1303.
228. Farago A, Nishizuka Y. Protein kinase C in transmembrane signalling. FEBS Lett 1990; 268: 350-354.
229. 3 to increase intracellular calcium and activate protein kinase C in mouse osteoblasts. J Cell Biochem 2003; 88: 794-801.
230. 3 which mediates rapid activation of protein kinase C. J Bone Miner Res 1998; 13: 1353-1359.
231. Boyan BD, Bone wald LF, Sylvia VL, Nemere I, Larsson D, Norman AW, et al. Evidence for distinct membrane receptors for 1 alpha, 25-(OH)(2)D(3) and 24R, 25-(OH)(2)D(3) in osteoblasts. Steroids 2002; 67: 235-246.
232. 3 membrane-associated rapid- response steroid binding protein during human tooth and Bone development and biomineralization. J Bone Miner Res 2002; 17: 1588-1596.
233. 3. J Bone Miner Res 1999; 14: 856-867.
234. Fleet JC. Vitamin D receptors: not just in the nucleus anymore. Nutr Rev 1999; 57: 60-62.
235. Wu S, Ren S, Chen H, Chun RF, Gacad MA, Adams JS. Intracellular vitamin D binding proteins: novel facilitators of vitamin D-directed transactivation. Mol Endocrine 2000; 14: 1387-1397.
236. Chun RF, Chen H, Boldrick L, Sweet C, Adams JS. Cloning, sequencing, and functional characterization of the vitamin D receptor in vitamin D-resistant New World primates. Am J Primatol 2001; 54: 107-118.
237. Wu S, Chun R, Gacad MA, Ren S, Chen H, Adams JS. Regulation of 1,25-dihydroxyvitamin d synthesis by intracellular vitamin d binding protein-1. Endocrinology 2002; 143: 4135-
238. 3 receptors and bioresponse in Bone cells: species differences between rat and mouse. Biochem Biophys Res Commun 1985; 132: 74-80.
239. 3 and dexamethasone on rat osteoblast-like primary cell cultures: receptor occupancy and functional expression patterns for three different bioresponses. Endocrinology 1986; 118: 250-259.
240. 3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995; 1: 997-1003.
241. 3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999; 140: 2071-2076.
242. Walters MR, Rosen DM, Norman AW, Luben RA. 1,25-Dihydroxyvitamin D receptors in an established Bone cell line. Correlation with biochemical responses. J Biol Chem 1982, 257: 7481-7484.
243. Henry HL, Norman AW, Taylor AN, Hartenbower DL, Coburn JW. Biological activity of 24, 25-dihydroxycholecalciferol in chicks and rats. J Nutr 1976; 106: 724-734.
244. 3 are both indispensable for calcium and phosphorus homeostasis. Life Sci 1980; 27: 229-237.
245. 3. Mol.Cell Endocrinol 2002; 197: 1-13.
246. 3 and Bone metabolism. Steroids 2001; 66: in press-
247. Boyan BD, Sylvia VL, Dean DD, Schwartz Z. 24, 25-(OH)(2)D(3) regulates cartilage and Bone via autocrine and endocrine mechanisms. Steroids 2001; 66: 363-374.
248. 3 on metalloproteinase activity and cell maturation in growth plate cartilage in vivo. Endocrine 2001; 14: 311-323.
249. 3 24R-hydroxylase activity in growth zone costochondral growth plate chondrocytes via protein kinase C. Calcif Tissue Int 2001; 69: 365-372.
250. 3 levels and Bone mass in 24-hydroxylase transgenic rats. FASEB J 2003; 17: 737-739.
251. Kasuga H, Hosogane N, Matsuoka K, Mori I, Sakura Y, Shimakawa K, et al. Characterization of transgenic rats constitutively expressing vitamin D-24-hydroxylase gene. Biochem Biophys Res Commun 2002; 297: 1332-1338.
252. Harant H, Spinner D, Reddy GS, Lindley IJ. Natural metabolites of 1alpha, 25-dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor. J Cell Biochem 2000; 78: 112-120.
253. 3 into new metabolites with significant biological activity: studies in rat osteosarcoma cells (UMR 106 and ROS 17/2.8). J Cell Biochem 2001; 82: 599-609.
254. 3 produced in rat osteosarcoma cells (UMR 106). J Nutr Sci Vitaminol (Tokyo) 2001; 47: 108-115.
255. 3 receptor by parathyroid hormone (PTH) and PTH-like peptide in osteoblast-like cells. Biochem Biophys Res Commun 1988; 156: 588-594.
256. 3 receptor gene expression by parathyroid hormone and cAMP-agonists. Biochem Biophys Res Commun 1992; 185: 881-886.
257. 3 on proliferation and vitamin D receptor expression of rat growth cartilage cells. Endocrinology 1994; 135: 1307-1315.
258. 3 receptors by parathyroid hormone in osteoblastic cells: role of second messenger pathways. Endocrinology 1995; 136: 705-712.
259. 3 is regulated by parathyroid hormone in UMR106 osteoblastic cells. Endocrinology 1998; 139: 3375-3381.
260. Van Leeuwen JP, Birkenhager JC, Schilte JP, Buurman CJ, Pols HA. Role of calcium and cAMP in heterologous up-regulation of the 1,25- dihydroxyvitamin D3 receptor in an osteoblast cell line. Cell Calcium 1990; 11: 281-289.
261. Huening M, Yehia G, Molina CA, Christakos S. Evidence for a regulatory role of inducible cAMP early repressor in protein kinase a-mediated enhancement of vitamin D receptor expression and modulation of hormone action. Mol Endocrinol 2002; 16: 2052-2064.
262. Chen C, Noland KA, Kalu DN. Modulation of intestinal vitamin D receptor by ovariectomy, estrogen and growth hormone. Mech Ageing Dev 1997; 99: 109-122.
263. 3 in T-47D human breast cancer cells. J.Steroid Biochem Mol Biol 1995; 54: 147-153.
264. 3 receptor in clonal osteoblast-like cells. Calcif Tissue Int 1991; 49: 35-42.
265. 3 action in osteoblast-like cells. Bone Miner 1994; 26: 27-42.
266. 3 receptor. Endocrinology 1992; 130: 2259-2266.
267. 3 receptors synergistically in rat osteosarcoma cells. Mol Cell Endocrinol 1994; 101: 159-165.
268. 3 binding in rat osteosarcoma cells. J Biol Chem 1984; 259: 8274-8280.
269. 3 receptor levels in tumor and nontumor cells derived from rat Bone J Natl Cancer Inst 1987; 78: 265-270.
270. Liel Y, Kraus S, Levy J, Shany S. Evidence that estrogens modulate activity and increase the number of 1,25-dihydroxyvitamin D receptors in osteoblast-like cells (ROS 17/2.8). Endocrinology 1992; 130: 2597-2601.
271. 3 receptors in T 47D breast cancer cells. J Steroid Biochem Mol Biol 1993; 45: 257-263.
272. 3 in human osteosarcoma-derived osteoblast-like cells. Calcif Tissue Int 1995; 57: 430-435.
273. Liel Y, Shany S, Smirnoff P, Schwartz B. Estrogen increases 1,25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa. Endocrinology 1999; 140: 280-285.
274. 3 receptors in Bone cells: changes with aging and hormone deprivation. Biochem Biophys Res Commun 2002; 299: 446-454.
275. Sriussadaporn S, Wong MS, Pike JW, Favus MJ. Tissue specificity and mechanism of vitamin D receptor up-regulation during dietary phosphorus restriction in the rat. J Bone Miner Res 1995; 10: 271-280.
276. 3 receptor in rat uterus. Biochem Biophys Res Commun 1981; 103: 721-726.
277. 3 receptor gene expression and enhances hormone action. Mol Endocrinol 1992; 6: 198-206.
278. 3. Endocrine 2002; 17: 109-118.
279. 3-induced differentiation of human osteoblasts. Exp Cell Res 2002; 275: 132-142.
280. Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999; 283: 1317-1321.
281. Yanagi Y, Suzawa M, Kawabata M, Miyazono K, Yanagisawa J, Kato S. Positive and negative modulation of vitamin D receptor function by transforming growth factor-beta signaling through smad proteins. J Biol Chem 1999; 274: 12971-12974.
282. 3. Crit Rev Eukaryot Gene Expr 2001; 11: 299-317.
283. Lindenmuth D, Van Wijnen AJ, Penman S, Stein JL, Stein GS, Lian JB. TGF-beta1 modifications in nuclear matrix proteins of osteoblasts during differentiation. J Cell Biochem 1998; 69: 291-303.
284. 3 and its interaction with glucocorticoids. Calcif Tissue Int 1984; 36: 580-585.
285. 3 on growth, alkaline phosphatase and adenylate cyclase of rat osteoblast-like cells. Bone Miner 1986; 1: 397-405.
286. 3. J Bone Miner Res 1992; 7: 303-309.
287. Li W, Farach-Carson MC. Parathyroid hormone-stimulated resorption in calvaria cultured in serum- free medium is enhanced by the calcium-mobilizing activity of 1,25- dihydroxyvitamin D(3). Bone 2001; 29: 231-235.
288. 3 on signaling by prostaglandin E2 in osteoblast- like cells. J Cell Biochem 1993; 52: 220-226.
289. Kozawa O, Tokuda H, Kotoyori J, Suzuki A, Ito Y, Oiso Y. Modulation of prostaglandin E2-induced Ca2+ influx by steroid hormones in osteoblast-like cells. Prostaglandins Leukot Essent Fatty Acids 1993; 49: 711-714.
290. 3 on prostaglandin E2 synthesis in osteoblast-like cells. Prostaglandins Leukot Essent Fatty Acids 1994; 51: 27-31.
291. 3 on interleukin-6 synthesis induced by prostaglandins in osteoblasts. Prostaglandins Leukot Essent Fatty Acids 1998; 58: 119-123.
292. 3 production. Studies in cultured mouse kidney cells. J Biol Chem 1995; 270: 25461-25467.
293. Wei S, Tanaka H, Seino Y. Local action of exogenous growth hormone and insulin-like growth factor- I on dihydroxyvitamin D production in LLC-PK1 cells. Eur J Endocrinol 1998; 139: 454-460.
294. Wong MS, Tembe VA, Favus MJ. Insulin-like growth factor-I stimulates renal 1,25- dihydroxycholecalciferol synthesis in old rats fed a low calcium diet. J Nutr 2000; 130: 1147-1151
295. Canalis E, Lian JB. Effects of Bone associated growth factors on DNA, collagen and osteocalcin synthesis in cultured fetal rat calvariae. Bone 1988; 9: 243-246.
296. 3 on regulation of function in clonal osteoblastic cells. Bone Miner 1989; 5: 335-345.
297. Liu P, Oyajobi BO, Russell RG, Scutt A. Regulation of osteogenic differentiation of human Bone marrow stromal cells: interaction between transforming growth factor-beta and 1,25(OH)(2) vitamin D(3) In vitro. Calcif Tissue Int 1999; 65: 173-180.
298. 2 vitamin D increases synergistically responsiveness to sex steroids in skeletal-derived cells. J Steroid Biochem Mol Biol 1995; 55: 211-217.
299. Chen FP, Lee N, Wang KC, Soong YK, Huang KE. Effect of estrogen and 1alpha, 25(OH)(2)- vitamin D(3) on the activity and growth of human primary osteoblast-like cells in vitro. Fertil Steril 2002; 77: 1038-1043.
300. 3-induced differentiation of human osteoblasts. Exp Cell Res 2002; 275: 132-142.
301. 3 inhibits thyroid hormone-induced osteocalcin expression in mouse osteoblast-like cells via a thyroid hormone response element. J Mol Endocrinol 2003; 30: 49-57.
302. D'ippolito G, Schiller PC, Perez-stable C, Balkan W, Roos BA, Howard GA. Cooperative actions of hepatocyte growth factor and 1,25- dihydroxyvitamin D(3) in osteoblastic differentiation of human vertebral Bone marrow stromal cells. Bone 2002; 31: 269-275.
303. 3 inhibits HGF synthesis and secretion from MG-63 human osteosarcoma cells. Am J Physiol Endocrinol Metab 2003; 284: E219-E227.
304. 3 on parathyroid hormone-related protein expression in human osteoblastic cells. J Bone Miner Res 2003; 18: 78-87.
305. Anissian L, Stark A, Dahistrand H, Granberg B, Good V, Bucht E. Cobalt ions influence proliferation and function of human osteoblast- like cells. Acta Orthop Scand 2002; 73: 369-374.
306. Narayanan R, Smith C, Weigel N. Vector-averaged gravity-induced changes in cell signaling and vitamin d receptor activity in MG-63 cells are reversed by a 1,25-(OH)(2)D(3) analog, EB1089. Bone 2002; 31: 381.
307. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995; 16: 200-257.
308. 3 analogues for the treatment of osteoporosis. Osteoporos Int 1993; 3 Suppl 1: 190-193.
309. 3 (ED-71), increases Bone mass by stimulating the Bone formation in normal and ovariectomized rats. Calcif Tissue Int 1994; 54: 142-149.
310. Uchiyama Y, Higuchl Y, Takeda S, Masaki T, Shira-Ishi A, Sato K, et al. ED-71, a vitamin D analog, is a more potent inhibitor of Bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 2002; 30: 582-588.
311. Peleg S, Uskokovic M, Ahene A, Vickery B, Avnur Z. Cellular and molecular events associated with the Bone -protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats. Endocrinology 2002; 143: 1625-1636.
312. 3 on Calcification in SV40-Transformed Human Fetal Osteoblastic Cells. Calcif Tissue Int 2002; 70: 488-495.
313. Shevde NK, Yamamoto H, Clagett-Dame M, Plum L, DeLuca HF, Pike JW. A novel vitamin D analogue exhibits selective anabolic actions in osteoblasts that result in enhanced Bone formation. J Bone Miner Res 2002; 17: S153.
314. 3 selectively induces Bone formation. Proc Natl Acad Sci USA 2002; 99: 13487-13491.
315. 3. J Cell Biochem 2003; 88: 267-273.
316. 3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J Biol Chem 2003; 278: 31756-31765.
317. 2 on Bone apposition from the inhibitory action of hydrocortisone in rats. Calcif Tissue Int 1981; 33: 167-172.
318. 2 analogs on calcium metabolism in vitamin D- deficient rats and in MC3T3-E1 osteoblastic cells. Res Exp Med (Berl) 1991; 191: 235-242.
319. Finch JL, Dusso AS, Pavlopoulos T, Slatopolsky EA. Relative potencies of 1,25-(OH)(2)D(3) and 19-Nor-1,25-(OH)(2)D(2) on inducing differentiation and markers of Bone formation in MG-63 cells. J Am Soc Nephrol 2001; 12: 1468-1474.
320. 3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts. Endocrinology 1996; 137: 1860-1869.
321. 3 in human osteoblasts. Mech Ageing Dev 2002; 123: 1107-1114.
322. 3 increases epidermal growth factor receptors and transforming growth factor beta-like activity in a Bone -derived cell line. J Biol Chem 1987; 262: 13424-13428.
323. Gonzalez EA, Disthabanchong S, Kowalewski R, Martin KJ. Mechanisms of the regulation of EGF receptor gene expression by calcitriol and parathyroid hormone in UMR 106-01 cells. Kidney Int 2002; 61: 1627-1634.
324. Kasperk CH, Borcsok I, Schairer HU, Schneider U, Nawroth PP, Niethard FU, et al. Endothelin-1 is a potent regulator of human Bone cell metabolism in vitro. Calcif Tissue Intl 997; 60: 368-374.
325. 3 responsive immediate early gene in human fetal osteoblasts: regulation by cytokines, growth factors, and serum. Endocrinology 1998; 139: 1761-1770.
326. Skjodt H, Hughes DE, Dobson PR, Russell RG. Constitutive and inducible expression of HLA class II determinants by human osteoblast-like cells in vitro. J Clin Invest 1990; 85: 1421-1426.
327. Horowitz MC, Coleman DL, Ryaby JT, Einhorn TA. Osteotropic agents induce the differential secretion of granulocyte- macrophage colony-stimulating factor by the osteoblast cell line MC3T3- E1. J Bone Miner Res 1989; 4: 911-921.
328. 3. J Clin Invest 1993; 91: 1731-1742.
329. Shen V, Cheng SL, Kohler NG, Peck WA. Characterization and hormonal modulation of IL-1 binding in neonatal mouse osteoblastlike cells. J Bone Miner Res 1990; 5: 507-515.
330. 3. J Cell Biochem 1993; 53: 122-134.
331. Tran JM, Kleeman CR, Green J. Production of interleukin-6 by osteoblastic cells is independent of medium inorganic phosphate. Biochem Mol Med 1995; 55: 90-95.
332. Gruber R, Nothegger G, Ho GM, Willheim M, Peterlik M. Differential stimulation by PGE(2) and calcemic hormones of IL-6 in stromal/osteoblastic cells. Biochem Biophys Res Commun 2000; 270: 1080-1085.
333. Littlewood AJ, Russell J, Harvey GR, Hughes DE, Russell RG, Gowen M. The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro. Endocrinology 1991; 129: 1513-1520.
334. Romas E, Udagawa N, Zhou H, Tamura T, Saito M, Taga T, et al. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in Bone marrow cultures. J Exp Med 1996; 183: 2581-2591.
335. Kirkwood KL, Dziak R, Bradford PG. Inositol trisphosphate receptor gene expression and hormonal regulation in osteoblast-like cell lines and primary osteoblastic cell cultures. J Bone Miner Res 1996; 11: 1889-1896.
336. Elford PR, Felix R, Cecchini M, Trechsel U, Fleisch H. Murine osteoblastlike cells and the osteogenic cell MC3T3-E1 release a macrophage colony-stimulating activity in culture. Calcif Tissue Int 1987; 41: 151-156.
337. 3 decrease the level of Na+-Ca2+ exchange protein in osteoblastic cells. Calcif Tissue Int 1997; 60: 473-478.
338. Jehan F, Naveilhan P, Neveu I, Harvie D, Dicou E, Brachet P, et al. Regulation of NGF, BDNF and LNGFR gene expression in ROS 17/2.8 cells. Mol Cell Endocrinol 1996; 116: 149-156.
339. 3-mediated nerve growth factor expression in osteoblasts. Biochemistry 1998; 37: 5988-5994.
340. 3 upregulates natriuretic peptide receptor-C expression in mouse osteoblasts. Am J Physiol 1998; 275: E965-E973.
341. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998; 139: 4743-4746.
342. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, Bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998; 250: 776-781.
343. O'Brien EA, Williams JH, Marshall MJ. Osteoprotegerin ligand regulates osteoclast adherence to the Bone surface in mouse calvaria. Biochem.Biophys Res Commun 2000; 274: 281-290.
344. 3 on growth factor secretion in co-cultures of osteoblasts and endothelial cells. Ultrasound Med Biol 2000; 26: 161-166.
345. 3 inhibits parathyroid hormone-related peptide mRNA expression in fetal rat long Bone s in culture. In vitro Cell Dev Biol Anim 1999; 35: 296-298.
346. 3 in human osteoblast-like cells. J Bone Miner Res 1996; 11: 472-479.
347. 3 induces the expression of vascular endothelial growth factor in osteoblastic cells. Endocr Res 1997; 23: 213-229.
348. 3 on osteoblasts are enhanced by vascular endothelial growth factor produced by osteoblasts and by growth factors produced by endothelial cells. Endocrinology 1997; 138: 2953-2962.
349. Blake GM, Fogelman I. The role of bone density measurements in the evaluation of new treatments for osteoporosis. Curr Pharm Design 2002; 8(21): 1885-1905.
350. Sambrook PN. Glucocorticoid osteoporosis. Curr Pharm Design 2002; 8(21): 1877-83.
351. Tucker KL. Dietary intake and bone status with aging. Curr Pharm Design 2003; 9(32): 2687-704.